Transdermal HA-LNP Delivery of PTEN mRNA for Skin Cancer The
2026-04-21
Transdermal HA-LNP Delivery of PTEN mRNA for Skin Cancer Therapy
Study Background and Research Question
Melanoma remains one of the most aggressive skin cancers, largely due to its propensity for rapid metastasis and resistance to current immunotherapies. While immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 have revolutionized treatment, fewer than half of patients achieve lasting clinical benefit. One key mechanism underlying resistance is the loss or mutation of the tumor suppressor gene PTEN, which normally inhibits the PI3K/Akt signaling pathway and promotes immune-mediated tumor clearance. PTEN deficiency not only drives uncontrolled proliferation but also impairs T cell infiltration and function, facilitating immune evasion by tumors (source: paper). This presents a compelling research question: can restoration of PTEN expression within tumors, via non-integrating, transient delivery of PTEN mRNA, reinstate antitumor immunity and improve therapeutic outcomes in melanoma?Key Innovation from the Reference Study
The reference study by Kim et al. reports a significant advance in localized cancer immunotherapy by developing a hyaluronate-conjugated lipid nanoparticle (HA-LNP) platform for transdermal delivery of PTEN mRNA. This HA-LNP system is engineered to enhance skin penetration, selectively target CD44-expressing tumor cells, and efficiently encapsulate large mRNA payloads without relying on polyethylene glycol (PEG), thereby reducing immunogenicity risks associated with PEGylated nanoparticles. The amphiphilic HA-dimyristoyl glycerol (HA-DMG) conjugate allows direct integration of hyaluronate into the lipid bilayer, providing both stability and CD44-mediated targeting in a single step (source: paper).Methods and Experimental Design Insights
The researchers synthesized HA-DMG as a scalable lipid conjugate, which was incorporated during the self-assembly of lipid nanoparticles. This approach avoided the need for post-formulation HA surface coating, simplifying the production workflow and enhancing reproducibility. PTEN mRNA was loaded into the HA-LNPs using established nanoparticle formulation techniques. The system was characterized for particle size, stability, mRNA encapsulation efficiency, and in vitro transfection capacity. In vitro assays were performed using melanoma cell models to assess restoration of PTEN expression, induction of immunogenic cell death (ICD), and reduction of cell viability. For in vivo studies, topical application of PTEN mRNA@HA-LNPs was carried out in melanoma-bearing mouse models to evaluate tumor penetration, suppression of tumor growth, and activation of antitumor immune responses (source: paper).Protocol Parameters
- mRNA transfection (in vitro) | 0.5–1.0 µg mRNA per well (24-well plate) | Melanoma cell line experiments | Established to optimize PTEN expression and minimize cytotoxicity | workflow_recommendation
- HA-LNP particle size | ~120 nm diameter | Ensures optimal tissue penetration and cell uptake | Correlated with efficient skin penetration and tumor targeting | paper
- Topical dosage (in vivo) | 15–30 µg PTEN mRNA per application | Mouse melanoma model | Balances effective tumor targeting with minimal off-target effects | paper
- Storage temperature for mRNA | -40°C or below | Maintains mRNA integrity for subsequent formulation | Prevents degradation during handling | product_spec
Core Findings and Why They Matter
The HA-LNP platform demonstrated several critical outcomes:- Efficient encapsulation and skin penetration: HA-LNPs stably encapsulated PTEN mRNA and penetrated deep into skin tissue when applied topically. This enabled delivery of the tumor suppressor gene mRNA directly to cutaneous tumors without invasive procedures (source: paper).
- Targeted uptake via CD44: The presence of hyaluronate facilitated selective uptake by CD44-positive tumor and immune cells, increasing specificity compared to traditional PEGylated LNPs (source: paper).
- Restoration of PTEN expression: In vitro, transfected melanoma cells showed robust PTEN protein production, leading to suppression of the PI3K/Akt pathway, increased cell death, and reduced viability. This suggests that tumor suppressor gene mRNA delivery can directly restore lost tumor-suppressing functions (source: paper).
- Immunogenic cell death and immune activation: Treated tumors exhibited markers of ICD and increased infiltration of cytotoxic T cells, consistent with re-engagement of antitumor immunity (source: paper).
- In vivo efficacy: Topical PTEN mRNA@HA-LNP application significantly inhibited tumor growth in mouse melanoma models, with minimal systemic toxicity (source: paper).
Comparison with Existing Internal Articles
Several internal resources contextualize and extend the relevance of these findings for translational researchers:- "Transdermal PTEN mRNA-HA-LNPs: Advancing Skin Cancer Immunotherapy" summarizes the core innovation in HA-LNP design and highlights the clinical promise of targeted, localized mRNA therapy for melanoma, reinforcing the study’s translational importance.
- "Translational Horizons in Cancer Biology: Leveraging Cap ..." reviews the mechanistic rationale for PTEN mRNA restoration and emphasizes the critical role of Cap 1-modified, poly(A)-tailed mRNA for maximizing translation and minimizing innate immune activation—attributes central to the studied platform.
- "Translating Tumor Suppressor mRNA into Clinical Impact: M..." further explores how advanced mRNA technologies, such as human PTEN mRNA with Cap 1 structure, are reshaping gene therapy research by enabling precise modulation of the PI3K/Akt pathway, which is directly addressed by the reference study’s approach.
Limitations and Transferability
While the HA-LNP system offers compelling advantages—including biocompatibility, scalable manufacturing, and non-invasive delivery—there are important limitations to consider:- Species specificity: Efficacy and safety were validated in mouse models; human translation will require further pharmacokinetic, safety, and immunogenicity studies (source: paper).
- Application scope: The platform is optimized for cutaneous tumors such as melanoma, where topical application and local delivery are feasible. Application to non-skin cancers would require alternative delivery strategies (workflow_recommendation).
- mRNA product attributes: While the study demonstrates efficacy with in vitro transcribed mRNA, the specific mRNA modifications (e.g., Cap 1 structure, poly(A) tail length, purity) are critical determinants of translation efficiency and immunogenicity. The transferability of outcomes depends on matching these quality attributes (source: internal_article).